Colorectal News and Research

RSS

New coverage for colorectal cancer screening to drive US markets for gastrointestinal endoscopy devices in 2010

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, new coverage instituted under the Patient Protection and Affordable Care Act of 2010 will remove the financial disincentives associated with colorectal cancer screening for a large segment of the US population. As a result of these changes in reimbursement, a growing number of colorectal cancer screening procedures will be performed through 2014, driving sales of many gastrointestinal endoscopy devices, including videoscopes and biopsy forceps.

20 Aug 2010

Trial shows positive results for radioembolisation technique for colorectal cancer liver metastases treatment

Using the innovative technique of radioembolisation to treat patients with inoperable colorectal cancer liver metastases who have failed all standard-of-care chemotherapy options can more than double the time until their disease progresses, according to the final results of a Phase III randomised controlled trial published in the prestigious Journal of Clinical Oncology.

20 Aug 2010

SIR-Spheres safe, effective for patients with colorectal cancer liver metastases who have failed chemotherapy

Radioactive yttrium-90 labelled resin microspheres (SIR-Spheres; Sirtex Medical, Sydney, Australia) appear to be a safe and effective treatment for patients with colorectal cancer liver metastases who have failed available chemotherapy options, according to the final results of a prospective clinical multi-centre phase II trial conducted by the Italian Society of Locoregional Therapies in Oncology (SITILO) and published in the British Journal of Cancer.

20 Aug 2010

Study reports uneven decline of colorectal cancer mortality rate

Black patients die from colorectal cancer at much higher rates than whites do and new research points to unequal health care as the cause. While deaths from colorectal cancer have declined over the past 40 years, the declines have been uneven, said lead author Samir Soneji, Ph.D., of the Robert Wood Johnson Health and Society Scholars Program at the University of Pennsylvania.

20 Aug 2010

Stand Up To Cancer prepares for next Team Fundraising Challenge

As part of a new long-term alliance, Stand Up To Cancer is gearing up for its next Team Fundraising Challenge by joining forces with one of television's most popular shows, Survivor on CBS. For the first time ever, Survivor will stand up and issue the "Challenge The Odds" Team Challenge with Stand Up To Cancer Ambassador and winner of Survivor: Africa, Ethan Zohn.

18 Aug 2010

USPTO grants Neogenix Oncology patent for DNAs encoding novel molecular aspects of NPC-1 antibody

Neogenix Oncology, Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued Patent No. 7,763,720, with claims related to DNAs encoding the novel molecular aspects of the Company's NPC-1 antibody.

18 Aug 2010

Breast cancer accomplice discovered

Scientists have discovered an accomplice in breast cancer - a master control switch with the power to set off a cascade of reactions orchestrated by a cancer-causing gene (or oncogene) named Wnt1. This executive molecule and its modus operandi are reported in back-to-back papers featured on the cover of the August 15 issue of Cancer Research.

18 Aug 2010

Cancer is the world's top 'economic killer,' report finds

The Associated Press: "Cancer is the world's top 'economic killer' as well as its likely leading cause of death, the American Cancer Society contends in a new report it will present at a global cancer conference in China this week. Cancer costs more in productivity and lost life than AIDS, malaria, the flu and other diseases that spread person-to-person, the report concludes.

18 Aug 2010

Cancer Institute of New Jersey expands 'Quality and Outcomes in Cancer Care Research Program'

Looking to gain further understanding about the impact of cancer on patients and families, The Cancer Institute of New Jersey (CINJ) is expanding its Quality and Outcomes in Cancer Care (QOCC) Research Program by welcoming nationally-recognized population science researcher Sharon Manne, PhD. Dr. Manne, who is the recipient of major grant awards from the National Institutes of Health (NIH) for her work in behavioral science, was most recently at the Fox Chase Cancer Center in Philadelphia. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

17 Aug 2010

Researchers find link between chronic inflammation and cancer

Virginia Commonwealth University Massey Cancer Center researchers have uncovered a new link between chronic inflammation and cancer. Although cancers do not always cause inflammation, chronic inflammation is known to help tumor cells grow.

17 Aug 2010

Use of estrogen alone does not increase lung cancer mortality in postmenopausal women: Study

Use of estrogen alone did not increase lung cancer mortality in postmenopausal women, according to a study published online August 13 in The Journal of the National Cancer Institute. In the Women's Health Initiative (WHI) trial, which consisted of several clinical trials on postmenopausal women, one study showed women with previous hysterectomy taking combined estrogen plus progestin therapy had a statistically significant increase in lung cancer mortality, but not incidence. Other studies with combined hormone therapy have had conflicting results. But the influence of estrogen alone was unclear.

16 Aug 2010

Pro-Pharmaceuticals second-quarter net loss applicable to common stock decreases to $2.5 million

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the second quarter and the first six months ended June 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.

13 Aug 2010

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.

12 Aug 2010

Amgen reports top-line results from Vectibix Phase 3 trial for head and neck cancer

Amgen today announced top-line results from a randomized Phase 3 trial evaluating Vectibix as a first-line treatment in patients with recurrent and/or metastatic squamous cell head and neck cancer. The data showed the addition of Vectibix to platinum-based chemotherapy did not result in a statistically significant improvement in overall survival, the primary endpoint, compared to chemotherapy alone.

12 Aug 2010

Insuring your health: Health law expands Medicare coverage of preventive care

In her latest Kaiser Health News consumer column, Michelle Andrews writes: "Preventive health care is important at any age, but never more so than as we get older.

11 Aug 2010

Dems continue push to sell health reform's benefits, GOP pushes back

The administration has struggled to sell senior citizens on the new health law, Politico reports. Here's why: "They know little about the early benefits the law has offered but remember last year's heated town halls, replete with death panels and rationing. And anti-health-reform rhetoric is generally proving to have considerable staying power."

11 Aug 2010

Myriad Genetics fourth-quarter revenues increase 9% to $93.9 million

Myriad Genetics, Inc. today reported financial results for its fourth quarter and fiscal year ended June 30, 2010.

11 Aug 2010

First Edition: August 10, 2010

In today's news, the House is back in town... though just for a day. Lawmakers will consider a state aid package that includes $16 billion in federal Medicaid assistance.

10 Aug 2010

Epitherix identifies potent and selective multiple chemical scaffolds against colorectal carcinoma

Epitherix, LLC, a privately held company focused on the discovery and development of novel Wnt pathway small molecule inhibitors for epithelial and leukemic cancers, today announced that it has identified multiple chemical scaffolds that are potent and selective against colorectal carcinoma. "We're very encouraged by our in vitro and in vivo data, especially considering the difficulty in drugging this pathway to date," said Dr. Osman Kibar, CEO of Epitherix.

10 Aug 2010

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma Inc. today reported financial results for the fourth quarter and full year of fiscal 2010.

10 Aug 2010

Colorectal News and Research

New coverage for colorectal cancer screening to drive US markets for gastrointestinal endoscopy devices in 2010

Trial shows positive results for radioembolisation technique for colorectal cancer liver metastases treatment

SIR-Spheres safe, effective for patients with colorectal cancer liver metastases who have failed chemotherapy

Study reports uneven decline of colorectal cancer mortality rate

Stand Up To Cancer prepares for next Team Fundraising Challenge

USPTO grants Neogenix Oncology patent for DNAs encoding novel molecular aspects of NPC-1 antibody

Breast cancer accomplice discovered

Cancer is the world's top 'economic killer,' report finds

Cancer Institute of New Jersey expands 'Quality and Outcomes in Cancer Care Research Program'

Researchers find link between chronic inflammation and cancer

Use of estrogen alone does not increase lung cancer mortality in postmenopausal women: Study

Pro-Pharmaceuticals second-quarter net loss applicable to common stock decreases to $2.5 million

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Amgen reports top-line results from Vectibix Phase 3 trial for head and neck cancer

Insuring your health: Health law expands Medicare coverage of preventive care

Dems continue push to sell health reform's benefits, GOP pushes back

Myriad Genetics fourth-quarter revenues increase 9% to $93.9 million

First Edition: August 10, 2010

Epitherix identifies potent and selective multiple chemical scaffolds against colorectal carcinoma

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News